Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03967223
Title Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)
Acronym IGNYTE-ESO
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors GlaxoSmithKline
Indications
Therapies
Age Groups: senior | child | adult
Covered Countries USA | NLD | ITA | GBR | FRA | ESP | CAN

Facility Status City State Zip Country Details
GSK Investigational Site Duarte California 91010 United States Details
GSK Investigational Site Stanford California 94305 United States Details
GSK Investigational Site Denver Colorado 80218 United States Details
GSK Investigational Site Jacksonville Florida 32224 United States Details
GSK Investigational Site Chicago Illinois 60637 United States Details
GSK Investigational Site Iowa City Iowa 52242-1009 United States Details
GSK Investigational Site Boston Massachusetts 02114 United States Details
GSK Investigational Site Ann Arbor Michigan 48109 United States Details
GSK Investigational Site Minneapolis Minnesota 55455 United States Details
GSK Investigational Site Rochester Minnesota 55905 United States Details
GSK Investigational Site Saint Louis Missouri 63110 United States Details
GSK Investigational Site New York New York 10065 United States Details
GSK Investigational Site Durham North Carolina 27710 United States Details
GSK Investigational Site Columbus Ohio 43210 United States Details
GSK Investigational Site Portland Oregon 97239 United States Details
GSK Investigational Site Pittsburgh Pennsylvania 15232 United States Details
GSK Investigational Site Nashville Tennessee 37203 United States Details
GSK Investigational Site Dallas Texas 75390-8565 United States Details
GSK Investigational Site Dallas Texas 75390-9063 United States Details
GSK Investigational Site Salt Lake City Utah 84112 United States Details
GSK Investigational Site Richmond Virginia 23298 United States Details
GSK Investigational Site Seattle Washington 98109-1024 United States Details
GSK Investigational Site Milwaukee Wisconsin 53226 United States Details
GSK Investigational Site Toronto Ontario M5G 2M9 Canada Details
GSK Investigational Site Montreal Quebec H1T 2M4 Canada Details
GSK Investigational Site Lyon cedex 08 69373 France Details
GSK Investigational Site Pessac cedex 33604 France Details
GSK Investigational Site Milano Lombardia 20133 Italy Details
GSK Investigational Site Rozzano (MI) Lombardia 20089 Italy Details
GSK Investigational Site Amsterdam 1066 CX Netherlands Details
GSK Investigational Site Barcelona 08025 Spain Details
GSK Investigational Site Hospitalet de Llobregat, Barcelona 08907 Spain Details
GSK Investigational Site Madrid 28040 Spain Details
GSK Investigational Site Sevilla 41013 Spain Details
GSK Investigational Site London SW3 6JJ United Kingdom Details
GSK Investigational Site London WC1E 6AG United Kingdom Details
GSK Investigational Site Manchester M20 4BX United Kingdom Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field